Coya Therapeutics, Inc. Common Stock (COYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $70.37M
Last updated: Nov 17, 2026 at 4:10 PM ET
Coya Therapeutics, Inc. Common Stock (COYA) Statistics
Coya Therapeutics, Inc. Common Stock (COYA) has a market cap of $70.37M and an enterprise value of $34.57M. It kept -643.45% of revenue as net income over the last 12 months. Its share count is up 40.19% from a year earlier.
Total Valuation
Enterprise value is 50.87% below the market cap, as cash exceeds debt.
| Market Cap | $70.37M |
|---|---|
| Enterprise Value | $34.57M |
| Latest price (Nov 17, 2026) | $3.02 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 15.1x and 2.1x. Its year-end P/S ranged from 12.2x to 24.0x from 2023 to 2025.
| P/S Ratio | 15.1x |
|---|---|
| Forward P/S | 88.3x |
| P/B Ratio | 2.1x |
Price Statistics
The stock is down 48.55% over 52 weeks and trades 28.61% below its 50-day average.
| Beta (1Y) | 1.83 |
|---|---|
| 52-Week Change | -48.55% |
| 1-Month Change | -28.10% |
| 3-Month Change | -39.24% |
| 6-Month Change | -33.92% |
| Total Return (1Y) | -48.55% |
| Total Return (3Y CAGR) | -17.35% |
| Return vs SPY (1Y) | -62.53% |
| Max Drawdown (1Y) | -56.84% |
| Max Drawdown (3Y) | -72.42% |
| Sharpe Ratio (1Y) | -1.15 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $4.23 |
| 200-Day Average | $4.55 |
| 52-Week Range | $2.72 to $6.62 |
| RSI (14 Days) | 33.1 |
| Average Volume (20 Days) | 179.57K |
Financial Position
Current assets cover 7.24x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.24x |
|---|---|
| Quick Ratio | 7.24x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -89.88% and return on assets is -76.74% over the last 12 months.
| Return on Equity (ROE) | -89.88% |
|---|---|
| Return on Assets (ROA) | -76.74% |
| Return on Capital Employed (ROCE) | -88.93% |
| ROA (5Y Average) | -68.67% |
| Asset Turnover | 0.13x |
Scores
COYA has an Altman Z-Score of 2.93, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.93 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $4.69M over the last 12 months is up 17.59% from the 12 months before.
| Revenue | $4.69M |
|---|---|
| Revenue Growth (YoY) | +17.59% |
| Gross Profit | $4.69M |
| Operating Income | -$31.67M |
| Pretax Income | -$32.28M |
| Net Income | -$30.17M |
| EBITDA | -$30.15M |
| EBIT | -$30.17M |
| Reported EPS (TTM) | -$1.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 85.38% of the $39.32M in total assets.
| Cash and Equivalents | $35.80M |
|---|---|
| Total Debt | $0 |
| Net Cash | $35.80M |
| Net Cash Per Share | $1.53 |
| Working Capital | $33.68M |
| Shareholder Equity | $33.57M |
| Book Value Per Share | $1.43 |
| Total Assets | $39.32M |
| Total Liabilities | $5.75M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$21.83M |
|---|---|
| FCF Per Share | -$0.93 |
| Depreciation and Amortization | $15.26K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -675.34%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -675.34% |
| Pretax Margin | -688.51% |
| Net Margin | -643.45% |
| EBITDA Margin | -643.06% |
| EBIT Margin | -643.38% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -14.35% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -14.35% |
Dividends and Yields
COYA does not pay a dividend.
| Buyback Yield | -44.19% |
|---|---|
| Shareholder Yield | -44.19% |
Peer Position
Against 4 similar companies, COYA has the 2nd highest P/S.
P/S RatioPeer median 7.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -42.77%
| P/S Ratio | 15.1x vs 7.0x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +17.59% vs -42.77% median |
Analyst Forecast
Consensus estimates put revenue growth at -20.36% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -20.36% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About COYA
What is COYA's market cap?
Coya Therapeutics, Inc. Common Stock has a market cap of $70.37M. Its enterprise value, which adds debt and subtracts cash, is $34.57M.
How many shares of COYA are outstanding?
Coya Therapeutics, Inc. Common Stock has 23.46M shares outstanding. The count is up 40.19% from a year earlier.
Does COYA pay a dividend?
No. Coya Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does COYA have?
Coya Therapeutics, Inc. Common Stock has $0 of total debt and $35.80M of cash and equivalents, a net cash position of $35.80M.
COYA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors